Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System

Elsevier, Clinical Colorectal Cancer, Volume 19, June 2020
Authors: 
Lau-Min K., Prakash P., Jo E., Thrift A.P., Hilsenbeck S., Musher B.L.
Metastatic colorectal cancer outcomes continue to improve, but they vary significantly by race and ethnicity. Hypothesizing that these disparities arise from unequal access to care rather than intrinsic biology, we showed that survival of 103 consecutive patients with metastatic colorectal cancer treated at an academic safety-net hospital that treats the underserved, predominantly minority population of Harris County, Texas, was superior to that of subjects enrolled in the CRYSTAL (Cetuximab Combined with Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer) trial. Our findings suggest that administering high-quality comprehensive cancer care to vulnerable populations can overcome disparities reported in the medical literature.

Category: